Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-HTN, for patients with uncontrolled hypertension. The Company anticipates releasing the top-line results of Target-HTN later this year.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

150 N. Radnor Chester Rd. F200
Radnor, PA 19087
USA

Phone

(888) 378-6240

Website

www.mineralystx.com

Email Address

Undisclosed

Overview

Mineralys Therapeutics is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension. We are driven to bring a targeted approach to the management of hypertension.

Profile

Social Media

Mineralys Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

BT Slingsby

Chief Executive Officer

Jon Congleton

Chief Financial Officer

Adam Levy

Chief Medical Officer

David Rodman

VP - Operations

Jessica Ibbitson

Browse more venture capital transactions:

Prev: 6/8/2022: Front Financial venture capital transaction
Next: 6/8/2022: Nava Benefits venture capital transaction

Share this article

About Database of VC Transactions

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary